Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsJeffrey Topal, MD
Associate Clinical ProfessorAbout
Research
Publications
2026
360: EVALUATION OF A BROAD-SPECTRUM ANTIBIOTIC MONITORING TOOL ACROSS A LARGE ACADEMIC HOSPITAL SYSTEM
Fal V, Tucker N, McManus D, Davis M, Russo P, Moss I, Topal J, Minella E, Santos E, Michno A. 360: EVALUATION OF A BROAD-SPECTRUM ANTIBIOTIC MONITORING TOOL ACROSS A LARGE ACADEMIC HOSPITAL SYSTEM. Critical Care Medicine 2026, 54 DOI: 10.1097/01.ccm.0001183436.02296.77.Peer-Reviewed Original ResearchP-50. Tigecycline for Refractory Vancomycin-Resistant Enterococcus Bacteremia
Nashar N, Holzworth A, Davis M, McSweeney T, McManus D, Topal J. P-50. Tigecycline for Refractory Vancomycin-Resistant Enterococcus Bacteremia. Open Forum Infectious Diseases 2026, 13: ofaf695.279. PMCID: PMC12792366, DOI: 10.1093/ofid/ofaf695.279.Peer-Reviewed Original ResearchVancomycin-resistant Enterococcus bacteremiaVancomycin-resistant EnterococcusClearance of bacteremiaVRE bacteremiaBlood culturesGt;72 hoursSterilization of blood culturesAllogeneic stem cell transplantationAssociated with significant morbidityImmunocompromised patient populationPositive blood culturesStem cell transplantationDuration of bacteremiaPrimary study endpointAcute myeloid leukemiaYale-New Haven HospitalIn-Hospital MortalityBacteremia recurrenceEnterococcus bacteremiaRefractory bacteremiaSalvage therapyLinezolid useTigecycline therapyEmpirical therapyAntibiotic therapyP-943. Evaluation of a broad-spectrum antibiotic monitoring tool across a large academic hospital system
Tucker N, McManus D, Davis M, Russo P, Moss I, Topal J, Fal V, Santos E, Michno A, Minella E. P-943. Evaluation of a broad-spectrum antibiotic monitoring tool across a large academic hospital system. Open Forum Infectious Diseases 2026, 13: ofaf695.1146. PMCID: PMC12792131, DOI: 10.1093/ofid/ofaf695.1146.Peer-Reviewed Original ResearchYale New Haven Health SystemElectronic medical recordsQuality of documentationPatient chartsQuality improvement assessmentAcademic hospital systemMedical chart reviewPharmacist workflowAntibiotic stewardship interventionsHealth systemPharmacist assessmentHospital systemPharmacistsFrontline pharmacistsAntibiotic ordersMedical recordsTherapy appropriatenessInterventionStewardship interventionsChart reviewBroad-spectrum antibioticsSame-dayStewardship challengesPatient demographicsAntimicrobial stewardship effortsP-944. Sniffing Out Antimicrobial Stewardship Opportunities Among Cases of Healthcare onset (HO) Clostridioides difficile infection (CDI)
Davis M, Topal J, Nashar N, McManus D. P-944. Sniffing Out Antimicrobial Stewardship Opportunities Among Cases of Healthcare onset (HO) Clostridioides difficile infection (CDI). Open Forum Infectious Diseases 2026, 13: ofaf695.1147. PMCID: PMC12792555, DOI: 10.1093/ofid/ofaf695.1147.Peer-Reviewed Original ResearchYale New Haven Health SystemHO-CDI casesAMS interventionsHO-CDICDI casesClostridioides difficile infectionCenters for Medicare and Medicaid ServicesCare team membersAntimicrobial stewardship opportunityAcute care hospitalsAntimicrobial stewardshipID consultation serviceAntibiotic useNational Healthcare Safety Network criteriaCommunity medical centerHealth systemMedicaid ServicesHospital systemPharmacy residentsHealthcare costsCare hospitalOutpatient antibiotic useTeam membersMedical CenterIntervention
2025
Clinical outcomes of metronidazole dosing strategies in obese patients with Bacteroides bloodstream infections
Shah S, Marini R, McManus D, Shields R, Topal J, Tate T. Clinical outcomes of metronidazole dosing strategies in obese patients with Bacteroides bloodstream infections. International Journal Of Antimicrobial Agents 2025, 67: 107701. PMID: 41455575, DOI: 10.1016/j.ijantimicag.2025.107701.Peer-Reviewed Original ResearchA mixed-methods study assessing the performance of a clinical decision support tool for Clostridioides difficile testing for patients receiving laxatives
Peaper D, Rathod S, Sussman L, Azar M, Murdzek C, Roberts S, Tichy E, Topal J, Kashyap N, McManus D, Martinello R. A mixed-methods study assessing the performance of a clinical decision support tool for Clostridioides difficile testing for patients receiving laxatives. Infection Control And Hospital Epidemiology 2025, 46: 497-503. PMID: 40079209, PMCID: PMC12034449, DOI: 10.1017/ice.2025.30.Peer-Reviewed Original ResearchClinical decision supportAdvanced practice providersClinical decision support alertsClinical decision support toolMixed-methods studyPractice providersClinician interactionClinician concernsPhysician's instructionsTest orderingAttending physiciansMixed-methodsDoses of laxativesPatient riskLaxative useClinicians' rationaleCliniciansDecision support toolHospitalized patientsStudy periodDecision supportAttendanceCase seriesAntibiotic exposureResidentsP-811. Telavancin for Refractory MRSA Bacteremia: A 10-Year Retrospective Review
Gander C, Singanamala S, Holzworth A, Rux C, McManus D, Davis M, Topal J. P-811. Telavancin for Refractory MRSA Bacteremia: A 10-Year Retrospective Review. Open Forum Infectious Diseases 2025, 12: ofae631.1003. PMCID: PMC11778060, DOI: 10.1093/ofid/ofae631.1003.Peer-Reviewed Original ResearchRefractory MRSA bacteremiaMethicillin-resistant Staphylococcus aureusBlood culture clearanceRetrospective chart reviewCulture clearanceSalvage regimenMRSA bacteremiaBlood culturesBaseline characteristicsMinimum inhibitory concentrationPrimary outcomeClinical success groupRecurrence of bacteremiaTreated with telavancinRecurrent bacteremiaRetrospective reviewNo significant differenceSingle-centerMechanism of actionClinical successSuccess groupTelavancinBacteremiaTreatment optionsOverall mortality
2024
Clinical outcomes of a twice-daily metronidazole dosing strategy for Bacteroides spp. bloodstream infections
Shah S, Adams K, Clarke L, Ludwig J, McManus D, Nguyen M, Topal J, Shields R. Clinical outcomes of a twice-daily metronidazole dosing strategy for Bacteroides spp. bloodstream infections. International Journal Of Antimicrobial Agents 2024, 65: 107403. PMID: 39667533, DOI: 10.1016/j.ijantimicag.2024.107403.Peer-Reviewed Original ResearchClinical failureDosing strategiesClinical outcomesIncreased risk of clinical failureRetrospective chart review of adult patientsChart review of adult patientsReview of adult patientsRate of clinical failureClinical outcomes of patientsRisk of clinical failureAssociated with worse outcomesOutcomes of patientsRetrospective chart reviewBloodstream infectionsMetronidazole doseAdult patientsWorse outcomesIncreased riskMetronidazolePatientsInclusion criteriaBacteroides sppBacteremiaDoseMortalityImproving cefazolin administration for surgical prophylaxis in reported penicillin allergy: A retrospective study of a health system intervention
Belmont A, Son M, Hyman J, You L, Su C, Kashyap N, Topal J, McManus D, Martinello R, Kwah J. Improving cefazolin administration for surgical prophylaxis in reported penicillin allergy: A retrospective study of a health system intervention. Journal Of Allergy And Clinical Immunology Global 2024, 4: 100377. PMID: 39830990, PMCID: PMC11742594, DOI: 10.1016/j.jacig.2024.100377.Peer-Reviewed Original ResearchPenicillin allergy labelHospital-wide guidelinesSurgical site infectionAllergy labelsSurgical patientsSevere allergic reactionsSurgical prophylaxisSite infectionAssociated with increased rates of surgical site infectionRate of surgical site infectionMulti-drug resistant infectionsAllergic reactionsPrevent surgical site infectionsFirst-line antibioticsFirst-line prophylaxisAdministration of cefazolinAssociated with increased ratesRetrospective cohort studyGuideline-directed therapyAdult surgical patientsPre-intervention groupPost-intervention groupPenicillin allergyPerioperative outcomesCefazolin administrationClinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis
Shah S, Clarke L, Davis M, Topal J, Shields R. Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis. Journal Of Antimicrobial Chemotherapy 2024, 79: 2017-2021. PMID: 38958234, PMCID: PMC12102595, DOI: 10.1093/jac/dkae205.Peer-Reviewed Original ResearchPseudomonas endocarditisFirst-lineClinical outcomesShorter time to treatment initiationFactors associated with treatment failureInvestigate clinical outcomes of patientsClinical outcomes of patientsTime to treatment initiationRate of adverse effectsProsthetic valve endocarditisFirst-line therapyOrgan transplant recipientsOutcomes of patientsInvestigate clinical outcomesIntracardiac complicationsDuke criteriaMicrobiological failureDrug discontinuationValve endocarditisCombination therapyTreatment failureTransplant recipientsDay mortalityInitial treatmentClinical benefit